JP7383627B2 - 新規トリアゾロン誘導体またはその塩、およびこれらを含む医薬組成物 - Google Patents

新規トリアゾロン誘導体またはその塩、およびこれらを含む医薬組成物 Download PDF

Info

Publication number
JP7383627B2
JP7383627B2 JP2020550176A JP2020550176A JP7383627B2 JP 7383627 B2 JP7383627 B2 JP 7383627B2 JP 2020550176 A JP2020550176 A JP 2020550176A JP 2020550176 A JP2020550176 A JP 2020550176A JP 7383627 B2 JP7383627 B2 JP 7383627B2
Authority
JP
Japan
Prior art keywords
triazol
dihydro
aminomethyl
fluoroprop
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020550176A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518384A (ja
JP2021518384A5 (cg-RX-API-DMAC7.html
Inventor
テ ドン ハン,
ヒ ジェ タク,
ウン キョン キム,
ス ビン チェ,
ソル パク,
ドン フン キム,
ソ ヨン キム,
ヒョン ホ チェ,
テ ワン キム,
ミ キョン チュ,
ナ ライ ハ,
ウィ チョル リ,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuhan Corp
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of JP2021518384A publication Critical patent/JP2021518384A/ja
Publication of JP2021518384A5 publication Critical patent/JP2021518384A5/ja
Priority to JP2023128580A priority Critical patent/JP2023145748A/ja
Application granted granted Critical
Publication of JP7383627B2 publication Critical patent/JP7383627B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2020550176A 2018-03-21 2019-03-20 新規トリアゾロン誘導体またはその塩、およびこれらを含む医薬組成物 Active JP7383627B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023128580A JP2023145748A (ja) 2018-03-21 2023-08-07 新規トリアゾロン誘導体またはその塩、およびこれらを含む医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020180032548A KR20190110736A (ko) 2018-03-21 2018-03-21 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR10-2018-0032548 2018-03-21
PCT/IB2019/052278 WO2019180646A1 (en) 2018-03-21 2019-03-20 Novel triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023128580A Division JP2023145748A (ja) 2018-03-21 2023-08-07 新規トリアゾロン誘導体またはその塩、およびこれらを含む医薬組成物

Publications (3)

Publication Number Publication Date
JP2021518384A JP2021518384A (ja) 2021-08-02
JP2021518384A5 JP2021518384A5 (cg-RX-API-DMAC7.html) 2022-03-11
JP7383627B2 true JP7383627B2 (ja) 2023-11-20

Family

ID=67986894

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020550176A Active JP7383627B2 (ja) 2018-03-21 2019-03-20 新規トリアゾロン誘導体またはその塩、およびこれらを含む医薬組成物
JP2023128580A Pending JP2023145748A (ja) 2018-03-21 2023-08-07 新規トリアゾロン誘導体またはその塩、およびこれらを含む医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023128580A Pending JP2023145748A (ja) 2018-03-21 2023-08-07 新規トリアゾロン誘導体またはその塩、およびこれらを含む医薬組成物

Country Status (10)

Country Link
US (2) US10995086B2 (cg-RX-API-DMAC7.html)
EP (1) EP3768675B1 (cg-RX-API-DMAC7.html)
JP (2) JP7383627B2 (cg-RX-API-DMAC7.html)
KR (2) KR20190110736A (cg-RX-API-DMAC7.html)
CN (1) CN111886233B (cg-RX-API-DMAC7.html)
AR (1) AR115007A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019237344B2 (cg-RX-API-DMAC7.html)
CA (1) CA3093057A1 (cg-RX-API-DMAC7.html)
TW (1) TWI803600B (cg-RX-API-DMAC7.html)
WO (1) WO2019180646A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190110736A (ko) * 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20200004036A (ko) * 2018-07-03 2020-01-13 주식회사유한양행 (e)-(2-(클로로메틸)-3-플루오로알릴)카바메이트 유도체의 제조방법
TWI835945B (zh) 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
AU2020206477B2 (en) 2019-01-11 2022-11-10 Transthera Sciences (Nanjing), Inc. Haloallylamine compounds and application thereof
KR20220145981A (ko) * 2021-04-22 2022-11-01 주식회사유한양행 트리아졸론, 테트라졸론, 및 이미다졸론, 또는 그의 염, 및 그를 포함하는 제약 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007523955A (ja) 2004-02-25 2007-08-23 ラ ホヤ ファーマシューティカル カンパニー 疾患の治療のためのアミンおよびアミド
WO2017046738A1 (en) 2015-09-15 2017-03-23 Glaxosmithkline Intellectual Property (No.2) Limited Triazolone compounds as perk inhibitors

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2725148A1 (de) 1977-06-03 1978-12-14 Hoechst Ag 1-aryl-4-alkyl-1,2,4-triazol-5-one und verfahren zu ihrer herstellung
US20050096360A1 (en) 2003-08-08 2005-05-05 Salter-Cid Luisa M. Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment of diseases
KR100572996B1 (ko) 2003-08-12 2006-04-25 한국화학연구원 불소화 비닐 에테르 측쇄기를 갖는 아졸계 살균제 화합물및 그의 제조방법
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US20070293548A1 (en) 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
EP2139333A4 (en) * 2007-03-28 2010-11-10 Merck Sharp & Dohme SUBSTITUTED PYRID- [3,2-E] - [1,2,4] -TRIAZOL- [4,3-C] -PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS
MX2009009920A (es) * 2007-03-29 2009-10-19 Hoffmann La Roche Inhibidores no nucleosidos de transcriptasa inversa.
GB0722075D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
US8426587B2 (en) 2007-11-21 2013-04-23 Pharmaxis Ltd. Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor
WO2010096722A1 (en) 2009-02-20 2010-08-26 Takeda Pharmaceutical Company Limited 3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2871793C (en) 2012-05-02 2020-09-15 Pharmaxis Ltd. Substituted 3-haloallylamine inhibitors of ssao and uses thereof
CN105143210A (zh) * 2013-04-25 2015-12-09 柳韩洋行 新的三唑酮衍生物或其盐以及含有其的药物组合物
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016092375A1 (en) * 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Substituted heterocycles as bromodomain inhibitors
WO2016101119A1 (en) 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Fused heteroaryl derivatives as orexin receptor antagonists
SG11201806700RA (en) 2016-02-12 2018-09-27 Pharmaxis Ltd Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof
EP3452469A1 (en) 2016-05-03 2019-03-13 Bayer Pharma Aktiengesellschaft Fluoroalkyl-substituted aryltriazole derivatives and uses thereof
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
CA3041169A1 (en) 2016-10-19 2018-04-26 Boehringer Ingelheim International Gmbh Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
CN110709385A (zh) 2017-03-02 2020-01-17 法玛西斯有限公司 赖氨酰氧化酶的卤代烯丙胺吡唑衍生物抑制剂及其用途
WO2018196677A1 (zh) 2017-04-28 2018-11-01 四川科伦博泰生物医药股份有限公司 氟代烯丙胺衍生物及其用途
FI3626699T3 (fi) 2017-06-20 2023-08-15 Shandong Danhong Pharmaceutical Co Ltd Ssao:n estäjä
CN109810041B (zh) 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
CN109988109B (zh) 2017-12-29 2020-12-29 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其用途
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110736A (ko) * 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN110938059A (zh) 2018-09-25 2020-03-31 上海轶诺药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
WO2020063854A1 (zh) 2018-09-27 2020-04-02 南京明德新药研发有限公司 作为vap-1抑制剂的喹啉类衍生物
EP3856176A4 (en) 2018-09-28 2022-05-04 Acucela Inc. INHIBITORS OF VAP-1
AU2019351124A1 (en) 2018-09-28 2021-05-20 Acucela Inc. Inhibitors of VAP-1
CN112789277B (zh) 2018-10-22 2022-11-04 广东东阳光药业有限公司 胍类衍生物及其用途
EP3870162A4 (en) 2018-10-24 2022-08-24 Metacrine, Inc. SSAO INHIBITORS AND USES THEREOF
TWI835945B (zh) 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
AU2020206477B2 (en) 2019-01-11 2022-11-10 Transthera Sciences (Nanjing), Inc. Haloallylamine compounds and application thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007523955A (ja) 2004-02-25 2007-08-23 ラ ホヤ ファーマシューティカル カンパニー 疾患の治療のためのアミンおよびアミド
WO2017046738A1 (en) 2015-09-15 2017-03-23 Glaxosmithkline Intellectual Property (No.2) Limited Triazolone compounds as perk inhibitors

Also Published As

Publication number Publication date
JP2021518384A (ja) 2021-08-02
EP3768675B1 (en) 2026-04-01
CA3093057A1 (en) 2019-09-26
EP3768675C0 (en) 2026-04-01
CN111886233A (zh) 2020-11-03
CN111886233B (zh) 2024-01-02
WO2019180646A1 (en) 2019-09-26
KR20200124759A (ko) 2020-11-03
TWI803600B (zh) 2023-06-01
US10995086B2 (en) 2021-05-04
US20210317110A1 (en) 2021-10-14
US11780830B2 (en) 2023-10-10
JP2023145748A (ja) 2023-10-11
EP3768675A4 (en) 2021-12-22
EP3768675A1 (en) 2021-01-27
US20190322655A1 (en) 2019-10-24
TW202003508A (zh) 2020-01-16
AR115007A1 (es) 2020-11-18
AU2019237344B2 (en) 2023-07-06
KR102788118B1 (ko) 2025-03-31
AU2019237344A1 (en) 2020-10-01
KR20190110736A (ko) 2019-10-01

Similar Documents

Publication Publication Date Title
US11780830B2 (en) Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same
AU2022288984B2 (en) 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
JP7322052B2 (ja) 新規アリールもしくはヘテロアリールトリアゾロン誘導体もしくはそれらの塩、またはそれを含む医薬組成物
US11820769B2 (en) Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same
HK40034427A (en) Novel triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230207

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230502

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230807

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231019

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231108

R150 Certificate of patent or registration of utility model

Ref document number: 7383627

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150